Abstract
A validation is described of the popular Lindmo assay which is widely used for the determination of immunoreactive fraction of radiolabeled monoclonal antibodies used in tumour targeting. 99mTechnetium-labelled PR1A3 anti-carcinoembryonic antigen (CEA) antibody was incubated with tumour cells bearing the appropriate CEA epitope over a range of concentrations and using optimized assay conditions. Cell-bound radioactivity was measured following centrifugation and the immunoreactive fraction determined by extrapolation of a Burke-Lineweaver plot to the y-axis. The specificity, repeatability, reproducibility, accuracy, sensitivity and linearity of the assay were explored and found to lie within acceptable limits.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
